Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:4058633rdf:typepubmed:Citationlld:pubmed
pubmed-article:4058633lifeskim:mentionsumls-concept:C0007806lld:lifeskim
pubmed-article:4058633lifeskim:mentionsumls-concept:C0031327lld:lifeskim
pubmed-article:4058633lifeskim:mentionsumls-concept:C0524850lld:lifeskim
pubmed-article:4058633lifeskim:mentionsumls-concept:C0026651lld:lifeskim
pubmed-article:4058633lifeskim:mentionsumls-concept:C0282638lld:lifeskim
pubmed-article:4058633lifeskim:mentionsumls-concept:C0027926lld:lifeskim
pubmed-article:4058633lifeskim:mentionsumls-concept:C0205321lld:lifeskim
pubmed-article:4058633pubmed:issue5lld:pubmed
pubmed-article:4058633pubmed:dateCreated1985-12-2lld:pubmed
pubmed-article:4058633pubmed:abstractTextMoxalactam, a new oxa-beta-lactam antibiotic, suggests a possible role in prophylaxis in neurosurgery. Therefore, CSF penetration of Moxalactam was determined in 12 patients with absence of clinical or laboratory evidence of meningitis. In the dose employed (25 mg/kg 3 times/day) CSF samples showed a penetration of Moxalactam through the blood-cerebrospinal barrier with concentrations higher than 0.1 microgram/ml which persisted for more than seven hours. The drug was well tolerated and adverse effects were not observed.lld:pubmed
pubmed-article:4058633pubmed:languageenglld:pubmed
pubmed-article:4058633pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4058633pubmed:citationSubsetIMlld:pubmed
pubmed-article:4058633pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:4058633pubmed:statusMEDLINElld:pubmed
pubmed-article:4058633pubmed:monthSeplld:pubmed
pubmed-article:4058633pubmed:issn0028-3819lld:pubmed
pubmed-article:4058633pubmed:authorpubmed-author:Sachsenheimer...lld:pubmed
pubmed-article:4058633pubmed:authorpubmed-author:KühnerAAlld:pubmed
pubmed-article:4058633pubmed:authorpubmed-author:FabriciusKKlld:pubmed
pubmed-article:4058633pubmed:issnTypePrintlld:pubmed
pubmed-article:4058633pubmed:volume28lld:pubmed
pubmed-article:4058633pubmed:ownerNLMlld:pubmed
pubmed-article:4058633pubmed:authorsCompleteYlld:pubmed
pubmed-article:4058633pubmed:pagination188-9lld:pubmed
pubmed-article:4058633pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:4058633pubmed:meshHeadingpubmed-meshheading:4058633-...lld:pubmed
pubmed-article:4058633pubmed:meshHeadingpubmed-meshheading:4058633-...lld:pubmed
pubmed-article:4058633pubmed:meshHeadingpubmed-meshheading:4058633-...lld:pubmed
pubmed-article:4058633pubmed:meshHeadingpubmed-meshheading:4058633-...lld:pubmed
pubmed-article:4058633pubmed:meshHeadingpubmed-meshheading:4058633-...lld:pubmed
pubmed-article:4058633pubmed:meshHeadingpubmed-meshheading:4058633-...lld:pubmed
pubmed-article:4058633pubmed:meshHeadingpubmed-meshheading:4058633-...lld:pubmed
pubmed-article:4058633pubmed:meshHeadingpubmed-meshheading:4058633-...lld:pubmed
pubmed-article:4058633pubmed:year1985lld:pubmed
pubmed-article:4058633pubmed:articleTitlePharmacokinetics and CSF penetration of moxalactam in antibiotic prophylaxis in neurosurgery.lld:pubmed
pubmed-article:4058633pubmed:publicationTypeJournal Articlelld:pubmed